Cargando…
Luminescent multiplex viability assay for Trypanosoma brucei gambiense
BACKGROUND: New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required. Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target organism in drug discovery. This may be attributed to the difficulties in handli...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728213/ https://www.ncbi.nlm.nih.gov/pubmed/23856321 http://dx.doi.org/10.1186/1756-3305-6-207 |
_version_ | 1782278824639070208 |
---|---|
author | Van Reet, Nick Pyana, Pati Rogé, Stijn Claes, Filip Büscher, Philippe |
author_facet | Van Reet, Nick Pyana, Pati Rogé, Stijn Claes, Filip Büscher, Philippe |
author_sort | Van Reet, Nick |
collection | PubMed |
description | BACKGROUND: New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required. Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target organism in drug discovery. This may be attributed to the difficulties in handling this subspecies and the lack of an efficient viability assay to monitor drug efficacy. METHODS: In this study, a T.b. gambiense strain, recently isolated in the D.R. Congo, was made bioluminescent by transfection with Renilla luciferase (RLuc) without altering its in vitro and in vivo growth characteristics. A luminescent multiplex viability assay (LMVA), based on measurement of the Renilla luciferase activity and the ATP content of the cells within the same experiment, was investigated as an alternative to the standard fluorimetric resazurin viability assay for drug sensitivity testing of T.b. gambiense. RESULTS: In a 96-well format, the RLuc transfected strain showed a detection limit of 2 × 10(4) cells ml(-1) for the Renilla luciferase measurement and 5 × 10(3) cells ml(-1) for the ATP measurement. Both assays of the LMVA showed linearity up to 10(6) cells ml(-1) and correlated well with the cell density during exponential growth of the long slender bloodstream forms. The LMVA was compared to the fluorimetric resazurin viability assay for drug sensitivity testing of pentamidine, eflornithine, nifurtimox and melarsoprol with both the wild type and the RLuc transfected population. For each drug, the IC(50) value of the RLuc population was similar to that of the wild type when determined with either the fluorimetric resazurin method or the LMVA. For eflornithine, nifurtimox and melarsoprol we found no difference between the IC(50) values in both viability assays. In contrast, the IC(50) value of pentamidine was higher when determined with the fluorimetric resazurin method than in both assays of the LMVA. CONCLUSIONS: LMVA has some advantages for viability measurement of T.b. gambiense: it requires less incubation time for viability detection than the fluorimetric resazurin assay and in LMVA, two sensitive and independent viability assays are performed in the same experiment. |
format | Online Article Text |
id | pubmed-3728213 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37282132013-08-01 Luminescent multiplex viability assay for Trypanosoma brucei gambiense Van Reet, Nick Pyana, Pati Rogé, Stijn Claes, Filip Büscher, Philippe Parasit Vectors Research BACKGROUND: New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required. Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target organism in drug discovery. This may be attributed to the difficulties in handling this subspecies and the lack of an efficient viability assay to monitor drug efficacy. METHODS: In this study, a T.b. gambiense strain, recently isolated in the D.R. Congo, was made bioluminescent by transfection with Renilla luciferase (RLuc) without altering its in vitro and in vivo growth characteristics. A luminescent multiplex viability assay (LMVA), based on measurement of the Renilla luciferase activity and the ATP content of the cells within the same experiment, was investigated as an alternative to the standard fluorimetric resazurin viability assay for drug sensitivity testing of T.b. gambiense. RESULTS: In a 96-well format, the RLuc transfected strain showed a detection limit of 2 × 10(4) cells ml(-1) for the Renilla luciferase measurement and 5 × 10(3) cells ml(-1) for the ATP measurement. Both assays of the LMVA showed linearity up to 10(6) cells ml(-1) and correlated well with the cell density during exponential growth of the long slender bloodstream forms. The LMVA was compared to the fluorimetric resazurin viability assay for drug sensitivity testing of pentamidine, eflornithine, nifurtimox and melarsoprol with both the wild type and the RLuc transfected population. For each drug, the IC(50) value of the RLuc population was similar to that of the wild type when determined with either the fluorimetric resazurin method or the LMVA. For eflornithine, nifurtimox and melarsoprol we found no difference between the IC(50) values in both viability assays. In contrast, the IC(50) value of pentamidine was higher when determined with the fluorimetric resazurin method than in both assays of the LMVA. CONCLUSIONS: LMVA has some advantages for viability measurement of T.b. gambiense: it requires less incubation time for viability detection than the fluorimetric resazurin assay and in LMVA, two sensitive and independent viability assays are performed in the same experiment. BioMed Central 2013-07-15 /pmc/articles/PMC3728213/ /pubmed/23856321 http://dx.doi.org/10.1186/1756-3305-6-207 Text en Copyright © 2013 Van Reet et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Van Reet, Nick Pyana, Pati Rogé, Stijn Claes, Filip Büscher, Philippe Luminescent multiplex viability assay for Trypanosoma brucei gambiense |
title | Luminescent multiplex viability assay for Trypanosoma brucei gambiense |
title_full | Luminescent multiplex viability assay for Trypanosoma brucei gambiense |
title_fullStr | Luminescent multiplex viability assay for Trypanosoma brucei gambiense |
title_full_unstemmed | Luminescent multiplex viability assay for Trypanosoma brucei gambiense |
title_short | Luminescent multiplex viability assay for Trypanosoma brucei gambiense |
title_sort | luminescent multiplex viability assay for trypanosoma brucei gambiense |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728213/ https://www.ncbi.nlm.nih.gov/pubmed/23856321 http://dx.doi.org/10.1186/1756-3305-6-207 |
work_keys_str_mv | AT vanreetnick luminescentmultiplexviabilityassayfortrypanosomabruceigambiense AT pyanapati luminescentmultiplexviabilityassayfortrypanosomabruceigambiense AT rogestijn luminescentmultiplexviabilityassayfortrypanosomabruceigambiense AT claesfilip luminescentmultiplexviabilityassayfortrypanosomabruceigambiense AT buscherphilippe luminescentmultiplexviabilityassayfortrypanosomabruceigambiense |